Facile synthesis of novel monocyclic *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams

Aman Bhalla,^{a,*} Shamsheer S. Bari,^a Shiwani Berry,^a Jitender Bhalla,^a Sunil Vats,^a Sanjay Mandal,^b and Sadhika Khullar^b

^a Department of Chemistry and Centre of Advanced Studies in Chemistry,
Panjab University, Chandigarh 160014, India

^b Indian Institute of Science Education and Research (IISER), Mohali 160062, India
E-mail: amanbhalla@pu.ac.in

DOI: <http://dx.doi.org/10.3998/ark.5550190.p009.172>

Abstract

A facile synthesis of novel monocyclic *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams (**5**, **6**) is described. The reaction of 2-methoxy/phenoxy/benzyl/phenylthio/seleno ethanoic acids or acetoxyacetyl chloride **4** with pyrazolyl substituted Schiff's bases **3a-d** using POCl₃ and Et₃N in refluxing toluene furnished β -lactams (**5**, **6**). These synthesized β -lactams have been characterized by spectroscopic techniques viz. NMR (¹H, ¹³C and ⁷⁷Se), FT-IR, mass spectrometry (EI-MS and HRMS) and elemental analysis. Single crystal X-ray crystallographic study of *trans*-1-(4'-methoxyphenyl)-3-methoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)azetidin-2-one **5p** has confirmed the molecular structure and the stereochemical outcome. The *cis* or *trans* configuration of β -lactams (**5**, **6**) was assigned with respect to position of C3-H and C4-H.

Keywords: β -Lactams, pyrazole derivatives, *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams, X-ray crystal structure

Introduction

β -Lactam heterocyclic compounds have been reported as synthons for the synthesis of amino acids, alkaloids and taxoids¹ and successfully used for medicinal applications, such as cholesterol acyl transferase inhibitors, thrombin inhibitors, human cytomegalovirus protease inhibitors, matrix-metallo protease inhibitors, human leukocyte elastase inhibitors, cysteine protease inhibitors, apoptosis inducers, gene activators, and β -turn nucleators.² The biological activity usually associated with the nature of the groups linked to N-1, C-3 and C-4 of the β -lactam molecules. Therefore, the construction of novel pyrazole substituted β -lactams with control of

functionality, stereochemistry and regioselectivity has remained a great challenge for the synthetic organic chemist in order to enhance their spectrum of biological activity, potency and specificity.

Pyrazole substituted heterocycles have a wide range of applications in agrochemicals, medicine and the pharmaceutical industry. 3,4-Disubstituted pyrazole derivatives have been shown to exhibit cyclin dependent kinase inhibitory activity and inhibited *in vitro* cellular proliferation in various human cells.³ A series of pyrazole derivatives have been showing high antiproliferative and antiangiogenic activities against human breast (MCF-7) and cervical carcinoma cells.^{4,6} Identification of antitumor activity of pyrazole oxime ethers has been well documented.⁷ Bonesi *et al.*⁸ synthesized a substituted pyrazole and investigated their potential activity as inhibitors of angiotensin converting enzyme (ACE). In literature, several reports have demonstrated substituted pyrazole and their derivatives as inhibitors of GSK3 β Glycogen synthase kinase,⁹ VEGFR2 kinase,¹⁰ tyrosinase,¹¹ phagocytosis of opsonized blood cells¹² and arylamine N-acetyltransferase.¹³

Bondock *et al.*,¹⁴ Radi *et al.*,¹⁵ Sahu *et al.*,¹⁶ Barsoum *et al.*¹⁷ and Burguete *et al.*¹⁸ have synthesized a series of substituted pyrazole and their derivatives possess antifungal, antimicrobial, antibacterial and anti-inflammatory activities. 4,5-Disubstituted pyrazoles have been shown to exhibit potent antiviral activity against a broad panel of viruses in different cell cultures (HEL Cell cultures) including hepatitis A virus and Herpes simplex virus type-I.^{19,20} Antidepressant and anticonvulsant activity of pyrazole derivatives has been reported by Abdel Aziz *et al.*²¹ The recent success of pyrazole derivatives as acyclonucleoside analogues,¹⁵ blockers of divalent metal transporter 1 (DMT1)²² and COX-2 inhibitors²³ has further highlighted the importance of this heterocyclic ring.

3-Methoxy- β -lactams have been found to have apoptotic activity against human leukemia, breast, prostate and head-neck cancer cells, thus exhibiting antitumor activity.²⁴ 3-Acetoxy/phenoxy- β -lactams serve as the precursors to taxol, taxotere (highly promising anticancer drugs).²⁵ 3-Benzyl/phenylthio/seleno- β -lactams have been reported to be synthons of biologically important heterocycles.²⁶ Encouraged by the broad spectrum of biological activity of pyrazole derivatives and β -lactams, it was planned to incorporate the pyrazolyl moiety into suitably substituted β -lactams to furnish novel pyrazole substituted β -lactam heterocycles.

In literature, very few reports are available for the synthesis of such type of molecules. Buttero *et al.*²⁷ have prepared 4-(pyrazol-4/5-yl)carbonyl-2-azetidinones *via* nitrilimine cycloaddition. Parmar *et al.*²⁸ have prepared β -lactams based on *N*-phenyl-3-phenyl-4-formyl pyrazole (PEP). Banik *et al.*²⁹ have recently reported the iodine/bismuth catalyzed synthesis of pyrrole substituted *N*-polyaromatic- β -lactams. Therefore, our present studies have been directed towards the synthesis of novel monocyclic *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams.

In previous studies we have demonstrated the synthesis of selenoalkanoic acids useful as β -lactam precursors,^{30,31} novel 3-thio/seleno- β -lactams and their Lewis acid mediated functionalization,³²⁻³⁸ stereoselective synthesis of *cis*- and *trans*-3-alkoxy- β -lactams,³⁹ spirocyclic- β -lactams,^{2,34,40} (*Z*)- and (*E*)-3-allylidene- β -lactams,⁴¹ 3-keto- β -lactams⁴² and

bicyclic- β -lactams.⁴³ Herein, we report the synthesis of novel monocyclic *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams (**5**, **6**).

Results and Discussion

The study began with the chloropyrazolecarbaldehyde **2**, prepared from the pyrazolinone **1** following a literature procedure⁴⁴ (Scheme 1). The pyrazole-substituted Schiff's bases **3a-d** were prepared by stirring equivalent amounts of an appropriate primary amine with the aldehyde **2** using molecular sieves (4Å) in dichloromethane (Scheme 1, Table 1). The structures of the novel Schiff's bases **3a-d** were confirmed on the basis of their NMR spectra (¹H, ¹³C) and CHN elemental analysis.

Scheme 1. Synthesis of pyrazolyl substituted Schiff's bases **3a-d**.

Table 1. Pyrazolyl substituted Schiff's bases **3a-d**

Entry	R^1	Schiff's base 3 ^b	Yield ^{a,b} (%)
1	C_6H_5	3a	85
2	$4-OCH_3C_6H_4$	3b	82
3	$CH_2C_6H_5$	3c	79
4	$4-ClC_6H_4$	3d	87

^a Yields quoted for pure, isolated products. ^b Isolated products characterized by NMR (¹H, ¹³C) and elemental analysis.

The synthesis of novel *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams **5-6** has been achieved *via* Staudinger cycloaddition between the Schiff's bases **3a-d** and a ketene generated from 2-substituted ethanoic acids or acid chloride **4**, respectively (Scheme 2).

Initially, 2-(phenylthio)ethanoic acid was reacted with Schiff's base **3a** using phosphorus oxychloride (POCl₃) and triethylamine (Et₃N) in dry methylene chloride at 0 °C, but this reaction did not afford the desired product. However, when the reaction was performed in refluxing dry toluene and the progress of the reaction was monitored by thin-layer chromatography (TLC), it resulted in the exclusive formation of *trans*-3-phenylthio-4-pyrazolyl- β -lactam **5a** in excellent

yield (Scheme 2, Table 2, Entry 1). The target product **5a** was purified by column chromatography on silica gel using ethyl acetate–hexane (10:90) as eluant and was identified as *trans*-1-(4'-methoxyphenyl)-3-phenylthio-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)azetidin-2-one on the basis of ^1H NMR spectroscopy.

Scheme 2. Synthesis of 3-acetoxy/methoxy/phenoxy/benzyl/phenylthio/seleno substituted 4-pyrazolyl- β -lactams **5a-m,o-r** and **6n-q,s**.

To understand the nature of the substituted ethanoic acids or acetoxyacetyl chloride **4** and the pyrazole substituted Schiff's bases **3a-d** towards Staudinger cycloaddition, the reaction was performed by altering the R, X and R^1 substituents i.e. $\text{R} = \text{C}_6\text{H}_5, \text{C}_6\text{H}_5\text{CH}_2, \text{CH}_3, \text{CH}_3\text{CO}$; $\text{X} = \text{O}, \text{S}, \text{Se}$; $\text{R}^1 = \text{C}_6\text{H}_5, \text{CH}_2\text{C}_6\text{H}_5, 4\text{-OCH}_3\text{C}_6\text{H}_4, 4\text{-ClC}_6\text{H}_4$ (Scheme 2, Table 2, Entries 1-19). A successful attempt has also been made towards the synthesis of *cis*-3-phenoxy/acetoxy-4-pyrazolyl- β -lactams **6n**, **6s** when the nitrogen atom in the Schiff's base **3** was substituted with a benzyl group (**3c**) instead of a *p*-methoxyphenyl or phenyl group (Scheme 2 and Table 2, entry 14, 19). However, 2-methoxyethanoic acid on treatment with Schiff's bases **3a-c** furnished *trans*- β -lactams **5o-q** as the major isomers along with *cis*- β -lactams **6o-q** as the minor isomers, respectively (Scheme 2, Table 2, Entry 15-17).

All these newly synthesized monocyclic *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams (**5**, **6**) were purified by column chromatography on silica gel using ethyl acetate-hexane (10:90) as the eluant.

The structures of these *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams (**5**, **6**) were established on the basis of various spectroscopic techniques viz., FTIR, NMR (^1H , ^{13}C , ^{77}Se), mass spectrometry (EI-MS and HRMS) and their elemental analysis (solid β -lactams only). The IR absorption band in the range $1724\text{-}1755\text{ cm}^{-1}$ for the $\text{C}=\text{O}$ of the β -lactam ring supported the formation of pyrazolyl- β -lactams **5**, **6**. The spatial juxtaposition of the C3-H and C4-H was assigned *trans* and *cis* in products **5**, **6** on the basis of coupling constant values ($J = 1.2\text{-}2.7\text{ Hz}$ and $J = 4.5\text{-}5.1\text{ Hz}$ C3-H and C4-H), respectively in the ^1H NMR spectra.^{35,39} The

stereochemistry at C-3 and C-4 of β -lactams **5**, **6** was established through single crystal X-ray crystallographic studies of **5p** (Figure 1).⁴⁵ In the EIMS spectrum of *trans*-3-methoxy-4-pyrazolyl- β -lactam **5p**, a peak corresponding to the fragment $[M+Na]^+$ with low intensity confirmed the formation of the target product. The base peak does not correspond to the molecular ion peak and appears at m/z 420.2 (100) $[M+Na]^+$, while the spectra display the molecular ion peak $[M+H]^+$ at m/z 398.2 (61), respectively. The other prominent peaks which are present at m/z 362.2 (28) and m/z 271.1 (10.87) corresponds to $[C_{21}H_{20}N_3O_3]^+$ and $[C_{13}H_{13}ClN_2NaO]^+$ respectively. CHN elemental analysis of the solid β -lactams (**5d**, **5f**, **5l**, **5m**, **6n**, **6p**, **6s**) and the HRMS analysis of β -lactams (**5a**, **5b**, **5c**, **5e**, **5g**, **5h**, **5i**, **5j**, **5k**, **5o**, **5q**, **5r**, **6o** and **6q**) further confirmed the formation of the target products.

Table 2. 3-Oxy/thio/seleno-4-pyrazolyl- β -lactams **5a-m,o-r** and **6n-q,s** (Scheme 2)

Entry	RX	R ¹	Yield ^a (%)		Mp (°C)
			<i>trans</i> - β -lactams 5	<i>cis</i> - β -lactams 6	
1	C ₆ H ₅ S	C ₆ H ₅	5a (79) ^c	—	Oil
2	C ₆ H ₅ S	4-CH ₃ OC ₆ H ₄	5b (74) ^c	—	Oil
3	C ₆ H ₅ S	CH ₂ C ₆ H ₅	5c (69) ^c	—	Oil
4	C ₆ H ₅ S	4-ClC ₆ H ₄	5d (52) ^d	—	164-165
5	C ₆ H ₅ CH ₂ S	C ₆ H ₅	5e (63) ^c	—	Oil
6	C ₆ H ₅ CH ₂ S	4-CH ₃ OC ₆ H ₄	5f (68) ^d	—	39-40
7	C ₆ H ₅ CH ₂ S	CH ₂ C ₆ H ₅	5g (56) ^c	—	Oil
8	C ₆ H ₅ Se	4-CH ₃ OC ₆ H ₄	5h (75) ^c	—	Oil
9	C ₆ H ₅ Se	CH ₂ C ₆ H ₅	5i (68) ^c	—	Oil
10	C ₆ H ₅ CH ₂ Se	C ₆ H ₅	5j (71) ^c	—	Oil
11	C ₆ H ₅ CH ₂ Se	4-CH ₃ OC ₆ H ₄	5k (66) ^c	—	Oil
12	C ₆ H ₅ O	C ₆ H ₅	5l (62) ^d	—	118-119
13	C ₆ H ₅ O	4-CH ₃ OC ₆ H ₄	5m (57) ^d	—	145-146
14	C ₆ H ₅ O	CH ₂ C ₆ H ₅	—	6n (61) ^d	109-110
15	CH ₃ O	C ₆ H ₅	5o (63) ^c	6o (20) ^c	Oil
16	CH ₃ O	4-CH ₃ OC ₆ H ₄	5p (65) ^{b,c}	6p (22) ^d	84-85/154-155
17	CH ₃ O	CH ₂ C ₆ H ₅	5q (55) ^c	6q (28) ^c	Oil
18	CH ₃ COO	4-CH ₃ OC ₆ H ₄	5r (64) ^c	—	Oil
19	CH ₃ COO	CH ₂ C ₆ H ₅	—	6s (69) ^d	123-124

^a Yields quoted are for the isolated products characterized by FT-IR, NMR (¹H, ¹³C, ⁷⁷Se). ^b The structure of this molecule was also established from single crystal X-ray data (Figure 1). ^c The

mass of the products were analyzed on the basis of EI-MS and HRMS (oily compounds).^d The products were characterized on the basis of CHN elemental analysis (solid compounds).

The *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams **5**, **6** are air- and moisture-stable, soluble in solvents such as dichloromethane, chloroform, acetone, toluene and ethyl acetate. *trans*-4-Pyrazolyl- β -lactams **5d**, **5f**, **5l**, **5m**, **5p** and *cis*-4-pyrazolyl- β -lactams **6n**, **6p**, **6s** were obtained as stable solids while the rest were obtained as yellowish brown oils.

Scheme 3. Plausible mechanism for synthesis of 3-oxy/thio/seleno-4-pyrazolyl- β -lactams **5**, **6**.

All these cycloaddition reactions were found to be highly stereoselective and indicate that the presence of different groups in the substrate moieties effect the stereochemical outcome of the desired pyrazolyl- β -lactams. The plausible mechanism for the formation of *trans*- and *cis*- β -lactams having a variety of substitutions at the C-3 position is depicted in Scheme 3. The synthesis of pyrazolyl- β -lactams proceeds with the generation of ketene **A** by treatment of 2-methoxy-/phenoxy/benzyl/phenylthio/phenylseleno ethanoic acids or acetoxyacetyl chloride **4** with phosphorus oxychloride and triethylamine in refluxing toluene. Further, the nucleophilic attack of the imino nitrogen of the *E*-imine on the face of the ketene **A** (RX = C₆H₅O, C₆H₅S, C₆H₅Se, C₆H₅CH₂S, C₆H₅CH₂Se CH₃O, CH₃COO) generating the zwitterionic intermediate **B** and **C** respectively, which on direct ring closure or conrotatory electrocycloization afforded the stereoselective *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams (**5**, **6**).

The plausible mechanism included above is in accordance with our earlier publication of stereoselective synthesis of *cis*- and *trans*-3-alkoxy- β -lactams,³⁹ where mechanistic aspects were discussed in detail with relevance to reports available in the literature.⁴⁸⁻⁵⁰ In the present work, all the 2-benzyl/phenylthio/seleno ethanoic acids (Moore ketenes having *S*/*Se*-alkyl or aryl groups) on treatment with pyrazolyl substituted imines gives *trans*- β -lactams as suggested in the literature.⁴⁸⁻⁵⁰ Whereas, the Bose-Evans ketenes (having *O*-alkyl or *O*-aryl groups) should give *cis*- β -lactams, which have been achieved in the synthesis of *cis*-3-methoxy/acetoxy- β -lactams with low yield. However, this cycloaddition did not afford the targeted products at lower temperature, therefore high temperature selectively favors the formation of predominantly *trans*- β -lactams. Further, competition between the rate of isomerisation and direct ring closure, temperature and substituents plays an important role towards the stereoselectivity of these Staudinger cycloadditions which is well documented in literature.^{39,48-50}

The crystal structure of *trans*-1-(4'-methoxyphenyl)-3-methoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)azetidin-2-one **5p** was established by X-ray crystallographic analysis (Figure 1).⁴⁵ It was crystallized from dichloromethane-hexane (3:1) as a colorless crystalline solid suitable for single crystal X-ray diffraction. A perspective view of the molecular structure with atom numbering has been given in Figure 1.

Figure 1. X-ray crystal structure of **5p**.

Figure 2. Hydrogen bonding interactions in **5p**.

Table 3. Hydrogen bonding interactions for compound **5p**

Entry	Intermolecular hydrogen bond (Å)	Bond Length (Å)
1.	O(2).....H(6)	2.505
2.	O(3).....H(3A)	2.612

A single crystal unit of β -lactam **5p** exhibit intermolecular hydrogen bonding interactions with two crystal units. The methoxy oxygen of [O(2)] of one crystal unit is showing hydrogen bonding with C4-H [H(6A)] of the other crystal unit. Whereas, carbonyl oxygen of the same

crystal unit [O(3)] shows hydrogen bonding with the phenyl hydrogen of the pyrazole ring [H(3A)] of the other crystal unit respectively (Figure 2, Table 3). In comparison to hydrogen bonding, quite weak intermolecular C–H interactions are also present.

Representatives of all these new *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams (**5**, **6**) have been submitted for Molecular Docking studies to examine their binding affinities/interactions which will be followed by *in vitro* screening of the best fit molecules for their bioactivities such as antibacterial, antitumor, antiviral and antimicrobial activity. Further elaboration of the pyrazole substituted β -lactams (**5**, **6**) to potential spirocyclic and bicyclic- β -lactams is underway in our laboratory.

Conclusions

In conclusion, a successful attempt has been made towards the synthesis of novel monocyclic *trans*- and *cis*-3-oxy/thio/seleno-4-pyrazolyl- β -lactams. Substrate scope was also investigated by varying the R, R¹ and X groups R = C₆H₅, C₆H₅CH₂, CH₃, CH₃CO; X = O, S, Se; R¹ = C₆H₅, CH₂C₆H₅, 4-OCH₃C₆H₄, 4-ClC₆H₄. The X-ray crystallographic analysis of compound **5p** allowed the stereochemistry at C-3 of *trans*- β -lactams **5** to be established.

Experimental Section

General. Melting points were determined in an open capillary on melting point apparatus Perfit GSI-MP-3. Fourier transform infrared spectra were recorded on a Thermo Scientific Nicolet iS50 (FTIR) spectrophotometer ($\nu_{\max}$ in cm⁻¹). ¹H (300 MHz), ¹³C (75 MHz) and ⁷⁷Se (57 MHz) NMR spectra were recorded on JEOL AL 300 (300 MHz) spectrometer. Chemical shifts are given in ppm relative to Me₄Si as an internal standard (δ = 0 ppm) for ¹H NMR, CDCl₃ (δ = 77.0 ppm) for ¹³C NMR spectra and Me₂Se (δ = 0 ppm) for ⁷⁷Se NMR spectra. The mass spectra (EI-MS and HRMS) were obtained using a Waters Q-TOF Micromass (YB361) spectrometer (permissible % error = 5-10 ppm). The elemental analysis (C, H, N) were recorded on Flash 2000 Organic elemental analyzer. Column chromatography was performed using Merck silica gel (60-120 mesh) using ethyl acetate-hexanes (10:90) as eluant system. Reactions were monitored by analytical thin-layer chromatography (TLC) using Merck silica gel G using ethyl acetate-hexanes (10:90) as an eluant system. For visualization, TLC plates were stained with iodine vapors or observed under UV light.

The reactions for the preparation of pyrazole substituted β -lactams were carried out under dry and deoxygenated nitrogen atmosphere. Phosphorus oxychloride (Merck), triethylamine (Qualigen), ethyl acetoacetate (Merck), phenylhydrazine (Hi-media) and all other commercially available compounds/reagents/solvents were of reagent grade quality and used without any further purification. Dimethylformamide and dichloromethane were dried and distilled over

anhydrous calcium chloride (CaCl_2) and phosphorus pentoxide (P_2O_5) respectively. Toluene was distilled under N_2 from sodium-benzophenone immediately before use.

Starting materials pyrazolone **1** and pyrazolecarbaldehyde **2** were prepared following the methods described in literature.⁴⁴ The IR, NMR, mass and elemental analysis for **1** [127-128 °C (literature⁴⁴ m.p. 128-130 °C)] and **2** [138-139 °C (literature⁴⁴ m.p. 140-141 °C)] are as given in the cited reference.

Typical procedure for the preparation of Schiff's bases 3a-d. A solution of the appropriate primary amine (1 mmol) and 5-chloro-3-methyl-1-phenyl-1*H*-pyrazole-4-carbaldehyde (1 mmol) in the presence of molecular sieves (4 Å) in dry methylene chloride (15 ml) was stirred at room temperature. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was filtered to remove the molecular sieves and the solvent was evaporated under vacuum to yield the imine, which was recrystallized from methylene chloride: hexane to afford a crystalline solid.

***N*-[5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)methylene]benzenamine (3a).** Yellow crystalline solid; yield 85%; mp 102-103 °C; ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.54 (3H, s, CH_3), 6.94-7.47 (10H, m, ArH), 8.29 (1H, s, $-\text{N}=\text{CH}-$); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 14.7, 114.8, 115.8, 118.3, 120.7, 124.8, 125.4, 128.1, 128.9, 129.0, 137.7, 150.4, 151.0, 152.8; Anal. Calcd. for $\text{C}_{17}\text{H}_{14}\text{ClN}_3$: C 69.03, H 4.77, N 14.21%. Found: C 68.87, H 4.73, N 14.13%.

***N*-[5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)methylene]-4-methoxybenzenamine (3b).** Yellow crystalline solid; yield: 82%; mp 117-119 °C; ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.54 (3H, s, CH_3), 3.70 (3H, s, OCH_3), 6.75-7.49 (9H, m, ArH), 8.31 (1H, s, $-\text{N}=\text{CH}-$); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 14.7, 55.2, 114.2, 116.0, 121.8, 124.8, 128.2, 128.5, 129.1, 137.8, 145.7, 149.2, 149.3, 150.3, 158.0; Anal. Calcd. for $\text{C}_{18}\text{H}_{16}\text{ClN}_3\text{O}$: C 66.36, H 4.95, N 12.90%. Found: C 66.20, H 4.92, N 12.85%.

***N*-[5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)methylene](phenyl)methanamine (3c).** Yellow crystalline solid; yield 79%; mp 129-131 °C; ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.54 (3H, s, CH_3), 4.75 (2H, s, CH_2), 7.21-7.53 (10H, m, ArH), 8.35 (1H, s, $-\text{N}=\text{CH}-$); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 14.7, 65.9, 115.3, 124.8, 126.7, 127.4, 127.5, 127.9, 128.1, 128.3, 128.4, 128.9, 137.8, 139.7, 150.3, 152.7, 152.8; Anal. Calcd. for $\text{C}_{18}\text{H}_{16}\text{ClN}_3$: C 69.79, H 5.21, N 13.56%. Found: C 69.61, H 5.18, N 13.49%.

4-Chloro-*N*-[5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)methylene]benzenamine (3d). Yellow crystalline solid; yield 87%; mp 153-154 °C; ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.79 (3H, s, CH_3), 7.16-7.39 (9H, m, ArH), 7.50 (1H, s, $\text{N}=\text{CH}$); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 12.8, 108.7, 120.2, 123.7, 126.4, 129.4, 130.2, 132.8, 133.0, 139.7, 147.3, 149.5, 160.3; Anal. Calcd. for $\text{C}_{17}\text{H}_{13}\text{Cl}_2\text{N}_3$: C 61.83, H 3.94, N 12.73%. Found: C 61.65, H 3.89, N 12.68%.

Typical procedure for preparation of β -lactams 5, 6. Phosphorus oxychloride (POCl_3 , 0.69 mmol, 1.5 equiv.) was added dropwise to a solution of 2-substituted ethanoic acid (0.55 mmol, 1.2 equiv.), Schiff's base (0.46 mmol, 1 equiv.) and triethylamine (1.38 mmol, 3 equiv.) under nitrogen atmosphere, at refluxing temperature, with constant stirring. The reaction mixture was

refluxed for 3-4 h. The solvent was evaporated and the crude product was extracted with CH₂Cl₂. The organic layer was washed with water (3 × 10 ml), 1N HCl (3 × 10 ml), 5% NaHCO₃ (3 × 10 ml) and brine (3 × 10 ml), then dried (Na₂SO₄) and concentrated. The residue was purified by silica gel column chromatography with hexane/EtOAc (90:10) as eluant to afford pure products.

1-Phenyl-3-phenylthio-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one

(5a). Yellowish brown oil; yield 79%; IR ($\nu_{\max}$, cm⁻¹): 1741 (C=O); ¹H NMR (300 MHz, CDCl₃): δ_{H} 2.21 (3H, s, CH₃), 4.45 (1H, d, ³*J*_{HH} 2.4 Hz, C4-H), 4.74 (1H, d, ³*J*_{HH} 2.7 Hz, C3-H), 6.94-7.48 (15H, m, ArH); ¹³C NMR (75 MHz, CDCl₃): δ_{C} 13.0, 54.4, 58.9, 111.7, 116.7, 119.8, 124.5, 124.7, 125.1, 126.1, 127.0, 128.2, 128.3, 129.0, 129.2, 129.4, 131.8, 132.6, 137.2, 137.8, 148.0, 162.6; HRMS (EI): *m/z* [M+H] Calcd. for C₂₅H₂₁ClN₃OS: 446.1093. Found: 446.1058.

***trans*-1-(4'-Methoxyphenyl)-3-phenylthio-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (5b).**

Yellowish brown oil; yield 74%; IR ($\nu_{\max}$, cm⁻¹): 1737 (C=O); ¹H NMR (300 MHz, CDCl₃): δ_{H} 2.19 (3H, s, CH₃), 3.64 (3H, s, OCH₃), 4.42 (1H, d, ³*J*_{HH} 2.4 Hz, C4-H), 4.69 (1H, d, ³*J*_{HH} 2.4 Hz, C3-H), 6.64-7.43 (14H, m, ArH); ¹³C NMR (75 MHz, CDCl₃): δ_{C} 12.9, 29.6, 54.2, 55.0, 55.1, 58.7, 111.7, 114.3, 114.4, 118.0, 124.5, 124.6, 126.0, 128.0, 128.1, 128.8, 129.1, 130.5, 130.6, 131.8, 131.9, 132.5, 137.7, 147.9, 156.3, 161.8; HRMS (EI): *m/z* [M+H] Calcd. for C₂₆H₂₃ClN₃O₂S: 476.1199. Found: 476.1131.

1-Benzyl-3-phenylthio-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one

(5c). Yellowish brown oil; yield 69%; IR ($\nu_{\max}$, cm⁻¹): 1752 (C=O); ¹H NMR (300 MHz, CDCl₃): δ_{H} 2.07 (3H, s, CH₃), 3.65 (1H, d, ³*J*_{HH} 15 Hz, CH₂), 4.10 (1H, d, ³*J*_{HH} 2.4 Hz, C4-H), 4.38 (1H, d, ³*J*_{HH} 1.8 Hz, C3-H), 4.62 (1H, d, ³*J*_{HH} 15 Hz, CH₂), 6.67-7.48 (15H, m, ArH); ¹³C NMR (75 MHz, CDCl₃): δ_{C} 12.6, 44.9, 52.9, 58.4, 111.2, 124.8, 126.2, 127.6, 128.2, 128.5, 128.7, 129.0, 129.2, 131.0, 134.2, 134.3, 137.9, 148.6, 164.9; HRMS (EI): *m/z* [M+H] Calcd. for C₂₆H₂₃ClN₃OS: 460.1250. Found: 460.1236.

1-(4'-chlorophenyl)-3-phenylthio-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (5d).

White crystalline solid; yield 52%; mp 164-165 °C; IR ($\nu_{\max}$, cm⁻¹): 1726 (C=O); ¹H NMR (300 MHz, CDCl₃): δ_{H} 2.20 (3H, s, CH₃), 4.90 (1H, d, ³*J*_{HH} 1.8 Hz, C3-H), 5.29 (1H, d, ³*J*_{HH} 1.8 Hz, C4-H), 6.82-7.46 (14H, m, ArH); ¹³C NMR (75 MHz, CDCl₃): δ_{C} 13.0, 55.7, 85.7, 110.8, 114.6, 114.8, 115.5, 118.2, 121.1, 122.5, 124.7, 126.1, 128.4, 129.0, 129.5, 129.7, 129.9, 130.0, 135.5, 137.7, 148.0, 156.9, 161.4; Anal. Calcd for C₂₅H₁₉Cl₂N₃OS: C, 62.50; H, 3.99; N, 8.75; S, 6.67%. Found: C, 62.32; H, 3.91; N, 8.67; S, 6.61%.

***trans*-1-Phenyl-3-benzylthio-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (5e).**

Yellowish brown oil; yield 63%; IR ($\nu_{\max}$, cm⁻¹): 1740 (C=O); ¹H NMR (300 MHz, CDCl₃): δ_{H} 2.08 (3H, s, CH₃), 3.82-3.93 (2H, m, ³*J*_{HH} 13.5 Hz, CH₂S), 4.15 (1H, d, ³*J*_{HH} 2.7 Hz, C4-H), 4.46 (1H, d, ³*J*_{HH} 2.7 Hz, C3-H), 6.96-7.45 (15H, m, ArH); ¹³C NMR (75 MHz, CDCl₃): δ_{C} 12.9, 29.7, 35.3, 54.8, 56.0, 111.7, 116.8, 124.4, 124.6, 124.7, 125.1, 126.0, 127.3, 128.2, 128.6, 128.9, 129.0, 129.1, 129.2, 137.2, 137.5, 137.7, 147.9, 162.9; HRMS (EI): *m/z* [M+H] Calcd. for C₂₆H₂₃ClN₃OS: 460.1250. Found: 460.1289.

***trans*-1-(4'-Methoxyphenyl)-3-benzylthio-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (5f).**

Yellowish solid; yield: 68%; mp 39-40 °C; IR ($\nu_{\max}$, cm⁻¹): 1743 (C=O);

^1H NMR (300 MHz, CDCl_3): δ_{H} 2.05 (3H, s, CH_3), 3.63 (3H, s, OCH_3), 3.79-3.90 (2H, dd, $^3J_{\text{HH}}$ 19.2 Hz, CH_2S), 4.09 (1H, d, $^3J_{\text{HH}}$ 2.4 Hz, C4-H), 4.37 (1H, d, $^3J_{\text{HH}}$ 2.4 Hz, C3-H), 6.66-7.40 (14H, m, ArH); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 12.8, 35.2, 54.6, 55.0, 56.0, 111.8, 114.3, 118.0, 124.5, 125.7, 127.2, 128.0, 128.5, 128.8, 129.0, 130.7, 137.6, 137.8, 147.8, 156.3, 161.8; Anal. Calcd. for $\text{C}_{27}\text{H}_{24}\text{ClN}_3\text{O}_2\text{S}$: C, 66.18; H, 4.94; N, 8.58%. Found: C, 65.97; H, 4.87; N, 8.47%.

trans-1-Benzyl-3-benzylthio-4-(5'-chloro-3'-methyl-1'-phenyl-1H-pyrazol-4'-yl)-azetidin-2-one (5g). Yellowish brown oil; yield 56%; IR (ν_{max} , cm^{-1}): 1756 ($\text{C}=\text{O}$); ^1H NMR (300 MHz, CDCl_3): δ_{H} 1.92 (3H, s, CH_3), 3.66 (1H, d, $^3J_{\text{HH}}$ 13.2 Hz, CH_2S), 3.79 (1H, d, $^3J_{\text{HH}}$ 14.7 Hz, CH_2N), 3.85 (1H, d, $^3J_{\text{HH}}$ 13.5 Hz, CH_2S), 3.99 (1H, d, $^3J_{\text{HH}}$ 2.4 Hz, C4-H), 4.07 (1H, d, $^3J_{\text{HH}}$ 2.4 Hz, C3-H), 4.52 (1H, d, $^3J_{\text{HH}}$ 14.7 Hz, CH_2N), 7.04-7.47 (15H, m, ArH); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 12.6, 35.1, 45.2, 54.2, 55.1, 111.4, 124.7, 126.0, 127.2, 127.9, 128.1, 128.5, 128.7, 128.9, 134.8, 134.8, 137.5, 137.9, 148.3, 165.1; HRMS (EI): m/z [$\text{M}+\text{H}$] Calcd. for $\text{C}_{27}\text{H}_{25}\text{ClN}_3\text{OS}$: 474.1406. Found: 474.1375.

trans-1-(4'-Methoxyphenyl)-3-phenylseleno-4-(5'-chloro-3'-methyl-1'-phenyl-1H-pyrazol-4'-yl)-azetidin-2-one (5h). Yellowish brown oil; yield 75%; IR (ν_{max} , cm^{-1}): 1735 ($\text{C}=\text{O}$); ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.15 (3H, s, CH_3), 3.65 (3H, s, OCH_3), 4.43 (1H, d, $^3J_{\text{HH}}$ 2.4 Hz, C4-H), 4.65 (1H, d, $^3J_{\text{HH}}$ 2.1 Hz, C3-H), 6.64-7.62 (14H, m, ArH); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 13.1, 23.5, 29.3, 29.8, 37.0, 43.6, 43.7, 48.4, 50.5, 52.1, 54.5, 55.1, 71.2, 108.0, 112.2, 114.5, 118.0, 124.7, 126.0, 126.2, 128.2, 128.8, 129.0, 129.3, 130.9, 135.6, 138.0, 148.0, 156.4, 162.6, 164.6, 172.4, 174.0; ^{77}Se NMR: δ_{Se} 350.5; HRMS (EI): m/z [$\text{M}+\text{H}$] Calcd. for $\text{C}_{26}\text{H}_{23}\text{ClN}_3\text{O}_2\text{Se}$: 524.0644. Found: 524.0699.

1-Benzyl-3-phenylseleno-4-(5'-chloro-3'-methyl-1'-phenyl-1H-pyrazol-4'-yl)-azetidin-2-one (5i). Yellowish brown oil; yield 68%; IR (ν_{max} , cm^{-1}): 1724 ($\text{C}=\text{O}$); ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.02 (3H, s, CH_3), 3.63 (1H, d, $^3J_{\text{HH}}$ 14.7 Hz, CH_2Ph), 4.08 (1H, d, $^3J_{\text{HH}}$ 2.1 Hz, C4-H), 4.39 (1H, d, $^3J_{\text{HH}}$ 2.1 Hz, C3-H), 4.53 (1H, d, $^3J_{\text{HH}}$ 14.7 Hz, CH_2Ph), 6.61-7.60 (15H, m, ArH). ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 12.6, 29.8, 32.0, 44.1, 45.1, 50.1, 53.3, 81.2, 111.5, 124.8, 126.1, 127.2, 127.6, 127.7, 128.2, 128.3, 128.6, 128.9, 129.0, 129.4, 129.5, 132.1, 134.4, 136.6, 150.3, 160.3, 164.1; HRMS (EI): m/z [$\text{M}+\text{Na}$] Calcd. for $\text{C}_{26}\text{H}_{22}\text{ClN}_3\text{NaOSe}$: 530.0514. Found: 530.0625.

1-Phenyl-3-benzylseleno-4-(5'-chloro-3'-methyl-1'-phenyl-1H-pyrazol-4'-yl)-azetidin-2-one (5j). Yellowish brown oil; yield 71%; mp 118-119 $^{\circ}\text{C}$; IR (ν_{max} , cm^{-1}): 1741 ($\text{C}=\text{O}$); ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.10 (3H, s, CH_3), 3.93-4.03 (2H, q, $^3J_{\text{HH}}$ 12 Hz, CH_2), 4.24 (1H, d, $^3J_{\text{HH}}$ 2.4 Hz, C4-H), 4.52 (1H, d, $^3J_{\text{HH}}$ 2.4 Hz, C3-H), 6.96-7.43 (15H, m, ArH); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 13.4, 14.6, 23.2, 27.9, 29.8, 29.9, 30.2, 32.4, 47.5, 50.8, 54.8, 54.9, 55.5, 112.5, 117.1, 117.2, 124.7, 125.1, 125.2, 126.5, 127.5, 128.7, 129.0, 129.2, 129.4, 129.6, 129.8, 136.0, 137.7, 137.9, 138.3, 138.6, 148.4, 148.5, 163.8, 164.0; HRMS (EI): m/z [$\text{M}+\text{H}$] Calcd. for $\text{C}_{26}\text{H}_{23}\text{ClN}_3\text{OSe}$: 508.0694. Found: 508.0660.

trans-1-(4'-Methoxyphenyl)-3-benzylseleno-4-(5'-chloro-3'-methyl-1'-phenyl-1H-pyrazol-4'-yl)-azetidin-2-one (5k). Yellowish brown oil; yield 66%; IR (ν_{max} , cm^{-1}): 1748 ($\text{C}=\text{O}$); ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.04 (3H, s, CH_3), 3.59 (3H, s, OCH_3), 3.86-3.95 (2H, dd, $^3J_{\text{HH}}$ 15.6, 15.9

Hz, CH₂Se), 4.20 (1H, d, ³J_{HH} 2.1 Hz, C4-H), 4.46 (1H, d, ³J_{HH} 2.7 Hz, C3-H), 6.65-7.38 (14H, m, ArH); ¹³C NMR (75 MHz, CDCl₃): δ_C 12.7, 27.2, 29.5, 39.0, 55.1, 111.8, 114.3, 117.9, 124.4, 125.8, 126.8, 128.0, 128.4, 128.8, 128.9, 130.7, 137.6, 138.1, 147.8, 156.2, 162.8.; ⁷⁷Se NMR: δ_{Se} 330.1; HRMS (EI): *m/z* [M+H] Calcd. for C₂₇H₂₅ClN₃O₂Se: 538.0800. Found: 538.0756.

1-Phenyl-3-phenoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (5l).

White crystalline solid; yield 62%; IR (ν_{max}, cm⁻¹): 1767 (C=O); ¹H NMR (300 MHz, CDCl₃): δ_H 2.25 (3H, s, CH₃), 4.98 (1H, d, ³J_{HH} 1.8 Hz, C4-H), 5.37 (1H, d, ³J_{HH} 1.8 Hz, C3-H), 6.86-7.50 (15H, m, ArH); ¹³C NMR (75 MHz, CDCl₃): δ_C 13.0, 55.6, 85.2, 110.9, 114.8, 115.3, 117.2, 120.1, 122.5, 124.8, 124.9, 126.5, 128.5, 129.1, 129.3, 129.7, 129.9, 136.7, 137.6, 148.3, 156.9, 157.1, 162.0, 166.2; Anal. Calcd. for C₂₅H₂₀ClN₃O₂: C, 69.85; H, 4.69; N, 9.77%. Found: C, 69.69; H, 4.63; N, 9.68%.

***trans*-1-(4'-Methoxyphenyl)-3-phenoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (5m).**

White crystalline solid; yield 57%; mp 145-146 °C; IR (ν_{max}, cm⁻¹): 1726 (C=O); ¹H NMR (300 MHz, CDCl₃): δ_H 2.07 (3H, s, CH₃), 3.64 (3H, s, OCH₃), 4.42 (1H, d, ³J_{HH} 2.4 Hz, C4-H), 4.69 (1H, d, ³J_{HH} 2.4 Hz, C3-H), 6.48-7.49 (14H, m, ArH); ¹³C NMR (75 MHz, CDCl₃): δ_C 11.2, 40.4, 55.2, 86.8, 114.1, 114.4, 119.0, 120.2, 120.4, 122.6, 126.4, 128.0, 129.0, 129.4, 134.2, 139.7, 147.6, 156.3, 157.5, 165.0; Anal. Calcd. for C₂₆H₂₂ClN₃O₃: C, 67.90; H, 4.82; N, 9.14%. Found: C, 67.72; H, 4.77; N, 9.06%.

1-Phenyl-3-methoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (5o).

Yellowish brown oil; yield 63%; IR (ν_{max}, cm⁻¹): 1731 (C=O); ¹H NMR (300 MHz, CDCl₃): δ_H 2.18 (3H, s, CH₃), 3.53 (3H, s, OCH₃), 4.64 (1H, d, ³J_{HH} 1.8 Hz, C4-H), 4.81 (1H, d, ³J_{HH} 1.8 Hz, C3-H), 6.97-7.45 (10H, m, ArH); ¹³C NMR (75 MHz, CDCl₃): δ_C 13.0, 54.6, 57.9, 88.7, 88.8, 111.8, 116.9, 124.4, 124.6, 125.6, 128.1, 128.9, 129.2, 137.1, 137.8, 147.8, 163.2; HRMS (EI): *m/z* [M+Na] Calcd. for C₂₀H₁₈ClN₃NaO₂: 390.0985. Found: 390.0936.

***trans*-1-(4'-Methoxyphenyl)-3-methoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (5p).**

Colorless crystalline solid; yield 65%; mp 84-85 °C; IR (ν_{max}, cm⁻¹): 1745 (C=O); ¹H NMR (300 MHz, CDCl₃): δ_H 2.19 (3H, s, CH₃), 3.55 (3H, s, OCH₃), 3.69 (3H, s, OCH₃), 4.64 (1H, d, ³J_{HH} 1.2 Hz, C4-H), 4.79 (1H, d, ³J_{HH} 1.2 Hz, C3-H), 6.72-7.47 (9H, m, ArH); ¹³C NMR (75 MHz, CDCl₃): δ_C 13.1, 53.6, 54.8, 55.2, 58.0, 58.7, 84.7, 88.9, 111.9, 114.5, 118.1, 118.3, 124.7, 125.8, 128.0, 128.2, 128.9, 129.0, 130.7, 130.8, 137.9, 148.0, 156.5, 162.8, 163.2; MS-EI (*m/z*): 420 (100, [M+Na]⁺), 398 (61, [M+H]⁺), 362 (28, [C₂₁H₂₀N₃O₃]⁺), 249 (4, [C₁₃H₁₃ClN₂O]⁺). Anal. Calcd. for C₂₁H₂₀ClN₃O₃: C, 63.40; H, 5.07; N, 10.56%. Found: C, 63.33; H, 5.07; N, 10.81%.

1-Benzyl-3-methoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (5q).

Yellowish brown oil; yield 55%; IR (ν_{max}, cm⁻¹): 1739 (C=O); ¹H NMR (300 MHz, CDCl₃): δ_H 2.07 (3H, s, CH₃), 3.45 (3H, s, OCH₃), 3.78 (1H, d, ³J_{HH} 14.7 Hz, CH₂), 4.19 (1H, d, ³J_{HH} 1.8 Hz, C4-H), 4.63 (1H, d, ³J_{HH} 1.8 Hz, C3-H), 4.70 (1H, d, ³J_{HH} 14.7 Hz, CH₂), 7.07-7.44 (10H, m, ArH); ¹³C NMR (75 MHz, CDCl₃): δ_C 13.6, 30.6, 32.0, 45.5, 54.5, 58.6, 89.3, 125.6, 128.8, 129.6, 129.7, 129.8, 158.1, 166.5; HRMS (EI): *m/z* [M+H] Calcd. for C₂₁H₂₁ClN₃O₂: 382.1322. Found: 382.1306.

***trans*-1-(4'-Methoxyphenyl)-3-acetoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (5r).** Yellowish brown oil; yield 64%; IR ($\nu_{\max}$, cm^{-1}): 1743 (C=O); ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.09 (3H, s, CH_3), 2.21 (3H, s, CH_3), 3.68 (3H, s, OCH_3), 4.80 (1H, d, $^3J_{\text{HH}}$ 1.8 Hz, C4-H), 5.58 (1H, d, $^3J_{\text{HH}}$ 1.8 Hz, C3-H), 6.71-7.46 (15H, m, ArH); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 12.9, 20.4, 29.7, 55.7, 60.8, 80.6, 111.0, 114.6, 118.5, 124.9, 126.3, 128.3, 128.9, 130.2, 137.8, 148.2, 156.8, 160.3, 169.2, 169.7, 171.4; HRMS (EI): m/z $[\text{M}+\text{Na}]$ Calcd. for $\text{C}_{22}\text{H}_{20}\text{ClN}_3\text{NaO}_4$: 448.1040. Found: 448.0980.

1-Benzyl-3-phenoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (6n). White crystalline solid; yield 61%; mp 109-110 °C; IR ($\nu_{\max}$, cm^{-1}): 1733 (C=O); ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.29 (3H, s, CH_3), 3.92 (1H, d, $^3J_{\text{HH}}$ 14.4 Hz, CH_2), 4.78 (1H, d, $^3J_{\text{HH}}$ 4.8 Hz, C4-H), 4.85 (1H, d, $^3J_{\text{HH}}$ 14.4 Hz, CH_2), 5.40 (1H, d, $^3J_{\text{HH}}$ 4.8 Hz, C3-H), 6.77-7.43 (15H, m, ArH); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 13.7, 29.8, 44.6, 53.1, 81.8, 109.0, 114.5, 115.0, 121.4, 122.0, 124.8, 127.1, 128.1, 128.7, 128.8, 128.9, 129.2, 129.5, 134.5, 138.0, 149.5, 156.7, 164.4; Anal. Calcd. for $\text{C}_{26}\text{H}_{22}\text{ClN}_3\text{O}_2$: C, 70.34; H, 5.00; N, 9.47%. Found: C, 70.19; H, 4.98; N, 9.39%.

1-Phenyl-3-methoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (6o). Yellowish brown oil; yield 20%; IR ($\nu_{\max}$, cm^{-1}): 1742 (C=O); ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.19 (3H, s, CH_3), 3.41 (3H, s, OCH_3), 4.74 (1H, d, $^3J_{\text{HH}}$ 5.1 Hz, C4-H), 5.18 (1H, d, $^3J_{\text{HH}}$ 3.6 Hz, C3-H), 6.97-7.52 (10H, m, ArH); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 13.2, 13.6, 22.2, 28.8, 28.9, 29.1, 29.6, 53.0, 58.5, 58.7, 84.0, 114.9, 116.2, 116.6, 123.9, 124.2, 124.3, 124.6, 127.4, 127.7, 128.3, 128.5, 128.7, 129.1, 157.5; HRMS (EI): m/z $[\text{M}+\text{Na}]$ Calcd. for $\text{C}_{20}\text{H}_{18}\text{ClN}_3\text{NaO}_2$: 390.0985. Found: 390.0936.

***cis*-1-(4'-Methoxyphenyl)-3-methoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (6p).** Colorless crystalline solid; yield 22%; mp 154-155 °C; IR ($\nu_{\max}$, cm^{-1}): 1749 (C=O); ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.21 (3H, s, CH_3), 3.45 (3H, s, OCH_3), 3.79 (3H, s, OCH_3), 4.79 (1H, d, $^3J_{\text{HH}}$ 4.8 Hz, C4-H), 5.20 (1H, d, $^3J_{\text{HH}}$ 4.8 Hz, C3-H), 6.77-7.57 (9H, m, ArH); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 13.9, 53.6, 55.2, 58.7, 84.7, 109.9, 114.5, 118.1, 124.7, 128.0, 128.9, 130.8, 138.2, 156.5, 163.2; Anal. Calcd. for $\text{C}_{21}\text{H}_{20}\text{ClN}_3\text{O}_3$: C, 63.40; H, 5.07; N, 10.56%. Found: C, 63.30; H, 5.02; N, 10.49%.

1-Benzyl-3-methoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (6q). Yellowish brown oil; yield 28%; IR ($\nu_{\max}$, cm^{-1}): 1755 (C=O); ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.20 (3H, s, CH_3), 3.32 (3H, s, OCH_3), 3.78 (1H, d, $^3J_{\text{HH}}$ 14.4 Hz, CH_2), 4.52 (1H, d, $^3J_{\text{HH}}$ 4.5 Hz, C4-H), 4.57 (1H, d, $^3J_{\text{HH}}$ 4.5 Hz, C3-H), 4.71 (1H, d, $^3J_{\text{HH}}$ 14.7 Hz, CH_2), 7.07-7.48 (10H, m, ArH); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 13.9, 44.3, 52.7, 58.5, 85.5, 109.7, 124.7, 126.9, 128.0, 128.7, 128.9, 134.8, 138.2, 149.9, 166.1; HRMS (EI): m/z $[\text{M}+\text{H}]$ Calcd. for $\text{C}_{21}\text{H}_{21}\text{ClN}_3\text{O}_2$: 382.1322. Found: 382.1306.

1-Benzyl-3-acetoxy-4-(5'-chloro-3'-methyl-1'-phenyl-1*H*-pyrazol-4'-yl)-azetidin-2-one (6s). White crystalline solid; yield 69%; mp 123-124 °C; IR ($\nu_{\max}$, cm^{-1}): 1731 (C=O); ^1H NMR (300 MHz, CDCl_3): δ_{H} 2.08 (3H, s, CH_3), 3.85 (1H, d, $^3J_{\text{HH}}$ 14.7 Hz, CH_2N), 4.68 (1H, d, $^3J_{\text{HH}}$ 4.8 Hz, C4-H), 4.82 (1H, d, $^3J_{\text{HH}}$ 14.7 Hz, CH_2N), 5.68 (1H, d, $^3J_{\text{HH}}$ 4.8 Hz, C3-H), 7.04-7.27 (10H, m,

ArH); ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 19.6, 44.7, 60.2, 60.9, 70.1, 128.1, 128.3, 128.7, 128.9, 132.3, 134.2, 165.0, 168.8, 170.1, 172.1; Anal. Calcd. for $\text{C}_{22}\text{H}_{20}\text{ClN}_3\text{O}_3$: C, 64.47; H, 4.92; N, 10.25%. Found: C, 64.32; H, 4.87; N, 10.13%.

Acknowledgements

A.B. gratefully acknowledges the financial support for this work from Department of Science and Technology (DST), New Delhi, Government of India, Project No. SR/FT/CS-037/2010 dated 28-10-2010. S.V., J.B. and S.B. acknowledge the financial support from University Grants Commission (UGC) vide sanction No. 10-2(5)/2005(ii)-E.U.II dated 10-05-2006, F.17-7(J) 2004 (SA-1) dated 03-10-2011 and F1-17.1/2011-12/RGNF-ST-HIM-9284/(SA-III/ web site) dated 06-06-2012 respectively.

Supporting Information

^1H and ^{13}C NMR spectra of some of representative β -lactams **5b**, **5f**, **5h**, **5k**, **5p**, **5r** and **6p**. EIMS spectra of **5p** and HRMS spectra of **5a**, **5b**, **5c**, **5e**, **5g**, **5h**, **5i**, **5j**, **5k**, **5o**, **5q**, **5r**.

References and Notes

1. Alcaide, B.; Almendros, P. *Chem. Soc. Rev.* **2001**, *30*, 226–240.
<http://dx.doi.org/10.1039/b007908l>
2. Bhalla, A.; Venugopalan, P.; Bari, S. S. *Eur. J. Org. Chem.* **2006**, 4943–4950 and references therein.
<http://dx.doi.org/10.1002/ejoc.200600458>
3. Lin, R.; Chiu, G.; Yu, Y.; Connolly, P. J.; Li, S.; Lu, Y.; Adams, M. Fuentes-Pesquera, A. R.; Emanuel, S. L.; Greenberger, L. M. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 4557–4561.
4. Peng-Cheng, L.; Zhu, H. -L.; Li, H. -Q.; Sun, J.; Zhou, Y. *Bioorg. Med. Chem.* **2010**, *18*, 4606–4614.
<http://dx.doi.org/10.1016/j.bmc.2010.05.034>
5. Christodoulou, M. S.; Sandra, L.; Kasiotis, K. M.; Harotounian, S. A. *Bioorg. Med. Chem.* **2010**, *18*, 4338–4350.
<http://dx.doi.org/10.1016/j.bmc.2010.04.076>
6. Vujasinovic, I.; Paravic, A.; Evic, R.; Milnaric-Majerski, K.; Brajsa, K.; Bertosa, B. *Bioorg. Med. Chem.* **2012**, *20*, 2101–2110.
<http://dx.doi.org/10.1016/j.bmc.2012.01.032>

7. Park, H. -J.; Lee, K.; Park, S. -J.; Ahn, B.; Lee, J. -C.; Cho, H. -Y.; Lee, K. -I. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3307–3312.
<http://dx.doi.org/10.1016/j.bmcl.2005.03.082>
8. Bonesi, M.; Loizzo, M. R.; Statti, G. A.; Michel, S.; Tillequin, F. M.; *Bioorg. Med. Chem. Lett.* **2010**, *20*, 1990–1993.
<http://dx.doi.org/10.1016/j.bmcl.2010.01.113>
9. Arnost, M.; Pierce, A.; Haar, E. T.; Lauffer, D.; Madden, J.; Tanner, K.; Green, J. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 1661–1664.
<http://dx.doi.org/10.1016/j.bmcl.2010.01.072>
10. Miyamoto, N.; Sakai, N.; Hirayama, T.; Miwa, K.; Oguro, Y.; Oki, H.; Okada, K.; Takagi, T.; Iwata, H.; Awazu, Y.; Yamasaki, S.; Takeuchi, T.; Miki, H.; Hori, A.; Imamura, S. *Bioorg. Med. Chem.* **2013**, *21*, 2333–2345.
<http://dx.doi.org/10.1016/j.bmc.2013.01.074>
11. Gawande, S. S.; Warangkar, S. C.; Bandgar, B. P.; Khobragade, C. N. *Bioorg. Med. Chem.* **2013**, *21*, 2772–2777.
<http://dx.doi.org/10.1016/j.bmc.2012.12.053>
12. Purohit, M. K.; Scovell, I.; Neschadim, A.; Katsman, Y.; Branch, D. R.; Kotra, L. P. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 2324–2327.
<http://dx.doi.org/10.1016/j.bmcl.2013.02.064>
13. Fullam, E.; Talbot, J.; Abuhammed, A.; Westwood, I.; Davies, S. G.; Russell, A. J.; Sim, E. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 2759–2364.
<http://dx.doi.org/10.1016/j.bmcl.2013.02.052>
14. Bondock, S.; Fadaly, W.; Metwally, M. A. *Eur. J. Med. Chem.* **2010**, *45*, 3692–3701.
<http://dx.doi.org/10.1016/j.ejmech.2010.05.018>
15. Radi, S.; Salhi, S.; Radi, A. *Lett. in Drug Design & Discovery* **2010**, *7*, 27–30.
16. Sahu, S. K.; Banerjee, M.; Samantray, A.; Behera, C.; Azam, M. A. *Tropical J. Pharm. Res.* **2008**, *7*, 961–968.
17. Barsoum, F. F.; Girgis, A. S. *Eur. J. Med. Chem.* **2009**, *44*, 2172–2177.
<http://dx.doi.org/10.1016/j.ejmech.2008.10.020>
18. Burguete, A.; Pontiki, E.; Hadjipavlou-Litina, D.; Villar, R.; Vicente, E.; Solano, B.; Ancizu, S.; Perez-Silanes, S.; Aldanaa, I.; Monge, A. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 6439–6343.
<http://dx.doi.org/10.1016/j.bmcl.2007.10.002>
19. El-Sabbagh, O. I.; Baraka, M. M.; Ibrahim, S. M.; Pannecouque, P.; Andrei, G.; Snoeck, R.; Balzarini, J.; Rashad, A. A. *Eur. J. Med. Chem.* **2009**, *44*, 3746–3753.
<http://dx.doi.org/10.1016/j.ejmech.2009.03.038>
20. Rashad, A. E.; Hegab, M. I.; Abdel-Megeid, R. E.; Micky, J. A.; Abdel-Megeid, F. M. E. *Bioorg. Med. Chem.* **2008**, *16*, 7102–7106.
<http://dx.doi.org/10.1016/j.bmc.2008.06.054>
21. Abdel-Aziz, M.; El-Din, A.; Abuo-Rahma, G.; Hassan, A. A. *Eur. J. Med. Chem.* **2009**, *44*, 3480–3487.

- <http://dx.doi.org/10.1016/j.ejmech.2009.01.032>
22. Cadieux, J. A.; Zhang, Z.; Mattice, M.; Brownlie-Cutts, A.; Fu, J.; Ratkay, L. G.; Kwan, R.; Thompson, J.; Sanghara, J.; Zhong, J.; Goldberg, Y. P. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 90–95.
<http://dx.doi.org/10.1016/j.bmcl.2011.11.069>
23. Baytas, S.; Dural, N. N. T.; Ozkan, Y.; Simsek, H. B.; Gursel, T.; Unlu, S. *Turk. J. Chem.* **2012**, *36*, 367–382.
<http://dx.doi.org/10.3906/kim-1110-8>
24. Smith, D. M.; Kazi, A.; Smith, L.; Long, T. E.; Heldreth, B.; Turos, E.; Dou, Q. P. *Mol. Pharmacol.* **2002**, *61*, 1348–1358.
25. Palomo, C.; Arrieta, A.; Cossio, F. P.; Aizpurua, J. M.; Mielgo, A.; Aurrekoetxea, N. *Tetrahedron Lett.* **1990**, *31*, 6429–6432.
26. Vanderveen, J. M.; Bari, S. S.; Krishana, L.; Manhas, M. S.; Bose, A. K. *J. Org. Chem.* **1989**, *54*, 5758–5762.
<http://dx.doi.org/10.1021/jm00038a001>
27. Buttero, P. D.; Molteni, G.; Pilati, T. *Tetrahedron Lett.* **2003**, *44*, 1425–1427.
PII: S 0 0 4 0 - 4 0 3 9 (0 2) 0 2 8 7 4 - 5
28. Parmar, K.; Sutariyaa, S.; Goswamia, K.; Dabhib, Y. *Der Chemica Sinica* **2012**, *3*, 1153–1156.
29. Bandyopadhyay, D.; Cruz, J.; Banik, B. K. *Tetrahedron* **2012**, *68*, 10686–10695.
<http://dx.doi.org/10.1016/j.tet.2012.06.009>
30. Bhalla, A.; Sharma, S.; Bhasin, K. K.; Bari, S. S. *Synth. Commun.* **2007**, *37*, 783–793.
<http://dx.doi.org/10.1080/00397910601133540>
31. Bhalla, A.; Nagpal, Y.; Kumar, R.; Mehta, S. K.; Bhasin, K. K.; Bari, S. S. *J. Organomet. Chem.* **2009**, *694*, 179–189.
<http://dx.doi.org/10.1016/j.jorganchem.2008.10.020>
32. Bhalla, A.; Madan, S.; Venugopalan, P.; Bari, S. S. *Tetrahedron* **2006**, *62*, 5054–5063.
<http://dx.doi.org/10.1016/j.tet.2006.03.050>
33. Bhalla, A.; Rathee, S.; Madan, S.; Venugopalan, P.; Bari, S. S. *Tetrahedron Lett.* **2006**, *47*, 5255–5259.
<http://dx.doi.org/10.1016/j.tetlet.2006.05.160>
34. Bhalla, A.; Venugopalan, P.; Bhasin, K. K.; Bari, S. S. *Tetrahedron* **2007**, *63*, 3195–3204.
<http://dx.doi.org/10.1016/j.tet.2007.02.001>
35. Bari, S. S.; Reshma; Bhalla, A.; Hundal, G. *Tetrahedron* **2009**, *65*, 10060–10068.
<http://dx.doi.org/10.1016/j.tet.2009.09.086>
36. Bari, S. S.; Bhalla, A.; Nagpal, Y.; Mehta, S. K.; Bhasin, K. K. *J. Organomet. Chem.* **2010**, *695*, 1979–1985.
<http://dx.doi.org/10.1016/j.jorganchem.2010.05.005>
37. Bhalla, A.; Bari, S. S.; Vats, S.; Sharma, M. L. *Res. J. Chem. Sci.* **2012**, *2*, 59–64.
38. Bari, S. S.; Bhalla, A.; Venugopalan, P.; Hundal, Q. *Res. J. Chem. Sci.* **2013**, *3*, 45–53.

39. Bhalla, A.; Venugopalan, P.; Bari, S. S. *Tetrahedron* **2006**, *62*, 8291–8302.
<http://dx.doi.org/10.1016/j.tet.2006.06.062>
40. Bari, S.S.; Bhalla, A.; Banik, B. (Ed.), *Topic in Heterocyclic Chemistry*, Springer, Berlin, Germany, 2010; pp 49–99.
41. Bari, S. S.; Arora, R.; Bhalla, A.; Venugopalan, P. *Tetrahedron Lett.* **2010**, *51*, 1719–1722.
<http://dx.doi.org/10.1016/j.tetlet.2010.01.085>
42. Bari, S. S.; Magtoof, M. S.; Bhalla, A. *Montash. Chem.* **2010**, *141*, 987–991.
<http://dx.doi.org/10.1007/s00706-010-0346-9>
43. Bari, S. S.; Bhalla, A.; Reshma; Hundal, G. *Tetrahedron Lett.* **2013**, *54*, 483–486 (and references therein).
<http://dx.doi.org/10.1016/j.tetlet.2012.11.062>
44. Xu, C. -J.; Shi, Y. -Q. *J. Chem. Crystallogr.* **2011**, *41*, 1816–1819.
<http://dx.doi.org/10.1007/s10870-011-0178-4>
45. Crystal data for **5p**: monoclinic, P 1 21/c 1, $a = 11.0168(8) \text{ \AA}$; $b = 12.0862(8) \text{ \AA}$; $c = 15.2820(11) \text{ \AA}$; $\alpha = 90^\circ$; $\beta = 101.541(4)^\circ$; $\gamma = 90^\circ$, $V = 1993.7(2) \text{ \AA}^3$, $Z = 4$, $\rho_{\text{Calcd}} = 1.325 \text{ Mg/cm}^3$, $\mu(\text{Mo-K}\alpha) = 0.71073 \text{ \AA}$, $T = 296(2) \text{ K}$, full matrix least-square on F^2 ; $R_1 = 0.0478$, $wR_2 = 0.1073$ for 3534 $[R(\text{int.}) = 0.0504]$ observed reflections $[I > 2\sigma(I)]$ and $R_1 = 0.1060$, $wR_2 = 0.1324$ for all 12183 reflections. Single crystals were mounted on glass capillaries of Bruker AXS KAPPA APEX II diffractometer using graphite-monochromated Mo $K\alpha$ radiation at room temperature. The data integration and reduction were processed with Bruker SAINT Software package. The crystal structures of **5p** was solved by direct methods using Bruker SHELXS-97⁴⁶ and refined by full-matrix least squares method. All the non-hydrogen atoms were refined anisotropically. The hydrogen atoms were included in the ideal position with fixed isotropic U values and were riding. The empirical absorption corrections for these compounds were performed using SADBAS program.⁴⁷ CCDC 963963 (**5p**) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
46. Sheldrick GM. SHELX-97 (Sheldrick 2008), programme for the solution and refinement of crystal structure. Goettingen, Germany; **1997**.
47. Sheldrick, G. M. Sdbas, Programme for empirical absorption of area detector data. University of Goettingen, Germany, **1996**.
48. Xu, J. *Arkivoc* **2009**, (ix), 21–44.
<http://dx.doi.org/10.3998/ark.5550190.0010.903>
49. Hegedus, L. S.; Montgomery, J.; Narukawa, Y.; Snustad, D. C. *J. Am. Chem. Soc.* **1991**, *113*, 5784–5791.
<http://dx.doi.org/10.1021/ja00015a036>
50. Davies, D.; Storr, A. In *Comprehensive Heterocyclic Chemistry*, Katritzky, A. Eds.; **1984**, vol. 7, pp. 237-284.